GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adial Pharmaceuticals Inc (NAS:ADIL) » Definitions » Retained Earnings

Adial Pharmaceuticals (Adial Pharmaceuticals) Retained Earnings : $-68.80 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Adial Pharmaceuticals Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Adial Pharmaceuticals's retained earnings for the quarter that ended in Dec. 2023 was $-68.80 Mil.

Adial Pharmaceuticals's quarterly retained earnings declined from Jun. 2023 ($-65.49 Mil) to Sep. 2023 ($-66.88 Mil) and declined from Sep. 2023 ($-66.88 Mil) to Dec. 2023 ($-68.80 Mil).

Adial Pharmaceuticals's annual retained earnings declined from Dec. 2021 ($-50.94 Mil) to Dec. 2022 ($-63.68 Mil) and declined from Dec. 2022 ($-63.68 Mil) to Dec. 2023 ($-68.80 Mil).


Adial Pharmaceuticals Retained Earnings Historical Data

The historical data trend for Adial Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adial Pharmaceuticals Retained Earnings Chart

Adial Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only -20.63 -31.52 -50.94 -63.68 -68.80

Adial Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -63.68 -66.58 -65.49 -66.88 -68.80

Adial Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Adial Pharmaceuticals  (NAS:ADIL) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Adial Pharmaceuticals (Adial Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1180 Seminole Trail, Suite 495, Charlottesville, VA, USA, 22901
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.
Executives
Kevin Schuyler director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Stilley William B. Iii director, 10 percent owner, officer: Chief Executive Officer 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Newman James W. Jr. director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Cary J Claiborne director 3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Bankole A. Johnson director, 10 percent owner 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Jack W Reich director C/O COLLATERAL THERAPEUTICS, 11622 EL CAMINO REAL, SAN DIEGO CA 92130
Tony Goodman director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
J. Kermit Anderson director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Joseph Truluck officer: COO and CFO 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Robertson H. Gilliland director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
En Fidecomiso De Mi Vida 11/23/2010 Trust 10 percent owner 11024 GAITHER FARM ROAD, ELLICOTT CITY MD 21042

Adial Pharmaceuticals (Adial Pharmaceuticals) Headlines